There are occasional conversations about the possibility of looking at a man’s fingers and predicting the aggressiveness of their prostate cancer. Is this real science or is this voodoo science? This might actually be real science! During gestation a male fetus’s development of the prostate gland is dependent on a functional androgen receptor and the [...]
Current Prognostic models for overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) have become dated. They don’t adequately reflect the many new drugs used in clinical practice. To develop a relevant model data from a phase III trial of 1,050 men with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]) was evaluated. [...]
Circulating tumor cells (CTCs) is an area we will continue to hear more about as their importance to our understanding prostate cancer continues to increase. CTCs show the movement of cancer cells though the body. It is believed that these CTCs are the method that cancer uses to spread through our body (metastasize). Measuring the [...]
Over the last several years’ prostate cancer treatment options for men with advanced prostate cancer has gone from rags to riches. We now have multiple options for treatment and there is every indication that the number of options will continue to grow. However, we do see that not all men will respond to all treatments. [...]
A large meta-analysis of nine studies showed that both oral and IV bisphosphonates were associated with a significantly increased risk of new-onset atrial-fibrillation (AF). The analysis also showed that the risk was greater with the IV drugs. According to the lead author, Dr Abhishek Sharma (Maimonides Medical Center, Brooklyn, NY.) the meta-analysis suggests that bisphosphonates [...]